A 52-year-old man with severe acute exacerbation of chronic obstructive pulmonary disease (COPD) is admitted to the ICU. He requires rapid anti-inflammatory effect and is unable to take oral medications. Which corticosteroid is the drug of choice for IV administration in this acute setting?

Explanation

## IV Corticosteroid Selection in Acute COPD Exacerbation **Key Point:** Methylprednisolone is the preferred IV corticosteroid for acute COPD exacerbation because it has rapid onset, high potency, excellent tissue penetration, and is available in parenteral formulation with proven efficacy in acute airway inflammation. ### Why Methylprednisolone is First-Line for IV Acute Therapy 1. **Rapid onset** — achieves therapeutic levels within 1–2 hours of IV administration; critical in acute respiratory compromise. 2. **High potency** (5× prednisolone) — provides rapid anti-inflammatory effect on airway mucosa and reduces bronchial edema. 3. **Parenteral availability** — formulated as sodium succinate salt for IV/IM use; no oral absorption required. 4. **Proven efficacy** — multiple RCTs demonstrate methylprednisolone IV reduces hospital length of stay and improves FEV₁ recovery in acute COPD exacerbation. 5. **Intermediate duration** (12–36 hours) — allows twice-daily dosing without excessive HPA suppression during acute phase. ### Comparison of IV Corticosteroids | Agent | Potency | Onset | Duration | Mineralocorticoid | Use in Acute COPD | |-------|---------|-------|----------|-------------------|-------------------| | **Methylprednisolone** | 5× | 1–2 hrs | 12–36 hrs | Minimal | **First-line IV** | | Hydrocortisone | 1× | 1–2 hrs | 8–12 hrs | High | Backup; requires frequent dosing | | Dexamethasone | 25–30× | 1–2 hrs | 36–72 hrs | Minimal | Too long-acting; not preferred | | Prednisolone | 4× | — | — | Yes | Oral only; not available IV | **High-Yield:** In acute exacerbations requiring IV therapy, **methylprednisolone 500–1000 mg IV 6-hourly** is the standard regimen. Hydrocortisone (100 mg IV 6-hourly) is an alternative but requires more frequent dosing. Dexamethasone is avoided because its prolonged action increases HPA suppression risk in acute illness. **Clinical Pearl:** After initial IV therapy (typically 48–72 hours), transition to oral prednisolone (0.5 mg/kg/day, tapering over 1–2 weeks) for continued immunosuppression without prolonged IV access. **Mnemonic:** **METH** for acute (Methylprednisolone = Acute, rapid, potent). **PRED** for chronic (Prednisolone = long-term, balanced). **Warning:** ~~Hydrocortisone~~ has lower potency (1×) and shorter duration (8–12 hours), requiring 6-hourly dosing; it is less convenient than methylprednisolone in acute settings. ~~Dexamethasone~~ is too long-acting and causes excessive HPA suppression in acute illness.